Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
October 30, 2025 07:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses...
October 25, 2025 09:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including...
October 23, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
October 20, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
October 06, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens...
August 25, 2025 07:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
August 20, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed...
August 07, 2025 06:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to...
July 28, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...